Citations

Mayo Clinic

Showing 10 of 108599 citations.

Eggerthella lenta augments preclinical autoantibody production and metabolic shift mimicking senescence in arthritis
Balakrishnan, Baskar , Luckey, David, Wright, Kerry , Davis, John M. , Taneja, Veena , Taneja, Veena , Davis, John M , Balakrishnan, Baskar , Chen, Jun

Science Advances | September 1, 2023 | Volume: 9 | Issue: 35 | Pages: No page available

10.1126/sciadv.adg1129 | PMID 37656793 Get It

Although the etiology of rheumatoid arthritis (RA) is unknown, a strong genetic predisposition and the presence of preclinical antibodies before the onset of symptoms is documented. An expansion of Eggerthella lenta is associated with severe disease in RA. Here, using a humanized mouse model of collagen-induced arthritis, we determined the impact of E. lenta abundance on RA severity. Naïve mice gavaged with E. lenta produce preclinical rheumatoid factor and, when induced for arthritis, develop severe disease. The augmented antibody response was much higher in female mice, and among patients with RA, women had higher average load of E. lenta . Expansion of E. lenta increased CXCL5 and CD4 T cells, and both interleukin-17– and interferon-γ–producing B cells. Further, E. lenta gavage caused gut dysbiosis and decline in amino acids and nicotinamide adenine dinucleotide with an increase in microbe-dependent bile acids and succinyl carnitine causing systemic senescent-like inflammation.
Optimal Transport Guided Unsupervised Learning for Enhancing Low-Quality Retinal Images
Zhu, Wenhui , Qiu, Peijie , Farazi, Mohammad , Nandakumar, Keshav, Dumitrascu, Oana M. , Wang, Yalin

2023 IEEE 20th International Symposium on Biomedical Imaging (ISBI) | September 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi53787.2023.10230719 | PMID 37736573 Get It

Correspondence on ‘Prevalence of pulmonary hypertension in aortic regurgitation and its influence on outcomes’ by Ratwatte et al
Michelena, Héctor I. , Anand, Vidhu , Enriquez‐Sarano, Maurice , Pellikka, Patricia A. , Pellikka, Patricia A , Michelena, Hector I , Enriquez-Sarano, Maurice

Heart | September 1, 2023 | Volume: 109 | Issue: 20 | Pages: 1574-1574

10.1136/heartjnl-2023-323347 | PMID 37657915 Get It

Development of a rapid lateral flow assay for detection of anti-coccidioidal antibodies
Grill, Francisca J. , Svarovsky, Sergei, González‐Moa, María J., Kaleta, Erin, Blair, Janis E. , Lovato, Lydia , Grant, Richard, Ross, Kyle, Linnehan, Barbara K. , Meegan, Jenny, Reilly, Kenta S., Brown, Ashlyn, Magee, D. Mitchell, Lake, Douglas F. , Grys, Thomas E , Lake, Douglas F , Ross, Kyle, Williams, Stacy , Chung, Yunro , Grys, Thomas E.

Journal of Clinical Microbiology | September 1, 2023 | Volume: 61 | Issue: 9 | Pages: No page available

10.1128/jcm.00631-23 | PMID 37655868 Get It

ABSTRACTCoccidioidesspp. are dimorphic fungi that are capable of infecting human and non-human mammals and can cause diverse manifestations of coccidioidomycosis or Valley fever (VF). In combination with clinical symptoms and radiographic findings, antibody-based diagnostic tests are often used to diagnose and monitor patients with VF. Chitinase 1 (CTS1) has previously been identified as the seroreactive antigen used in these diagnostic assays to detect anticoccidial IgG. Here, an indirect enzyme-linked immunosorbent assay to detect IgG to CTS1 demonstrated 165 of 178 (92.7%) patients with a positive result by immunodiffusion (ID) and/or complement fixation (CF) had antibodies to the single antigen CTS1. We then developed a rapid antibody lateral flow assay (LFA) to detect anti-CTS1 antibodies. Out of 143 samples tested, the LFA showed 92.9% positive percent agreement [95% confidence interval (CI), 84.3%–96.9%] and 97.7% negative percent agreement (95% CI, 87.9%–99.6%) with ID and CF assays. Serum or plasma from canines, macaques, and dolphins was also tested by the CTS1 LFA. Test line densities of the CTS1 LFA correlated in a linear manner with the reported CF and ID titers for human and non-human samples, respectively. This 10-min point-of-care test for the rapid detection of anti-coccidioidal antibodies could help to inform healthcare providers in real-time, potentially improving the efficiency of healthcare delivery.
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response
Ager, Casey R. , Zhang, Mingxuan , Chaimowitz, Matthew G., Bansal, Shruti, Tagore, Somnath, Jugler, Collin , Rogava, Meri , McCann, Patrick J. , Spina, Catherine, Drake, Charles G. , Izar, Benjamin , Izar, Benjamin , Tagore, Somnath , Obradović, Aleksandar , Melms, Johannes C. , McCann, Patrick, Dallos, Matthew C. , McCann, Patrick J.

Journal for ImmunoTherapy of Cancer | September 1, 2023 | Volume: 11 | Issue: 9 | Pages: e006782

10.1136/jitc-2023-006782 | PMID 37657842 Get It

Current methods for biomarker discovery and target identification in immuno-oncology rely on static snapshots of tumor immunity. To thoroughly characterize the temporal nature of antitumor immune responses, we developed a 34-parameter spectral flow cytometry panel and performed high-throughput analyses in critical contexts. We leveraged two distinct preclinical models that recapitulate cancer immunoediting (NPK-C1) and immune checkpoint blockade (ICB) response (MC38), respectively, and profiled multiple relevant tissues at and around key inflection points of immune surveillance and escape and/or ICB response. Machine learning-driven data analysis revealed a pattern of KLRG1 expression that uniquely identified intratumoral effector CD4 T cell populations that constitutively associate with tumor burden across tumor models, and are lost in tumors undergoing regression in response to ICB. Similarly, a Helios-KLRG1+ subset of tumor-infiltrating regulatory T cells was associated with tumor progression from immune equilibrium to escape and was also lost in tumors responding to ICB. Validation studies confirmed KLRG1 signatures in human tumor-infiltrating CD4 T cells associate with disease progression in renal cancer. These findings nominate KLRG1+ CD4 T cell populations as subsets for further investigation in cancer immunity and demonstrate the utility of longitudinal spectral flow profiling as an engine of dynamic biomarker discovery.
The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA
Fishman, Jesse , Wilson, Koo , Pochopień, Michał, Dingli, David , Dingli, David , Drzewiecka, Aleksandra

Journal of Comparative Effectiveness Research | September 1, 2023 | Volume: 12 | Issue: 10 | Pages: No page available

10.57264/cer-2023-0055 | PMID 37655691 Get It

Aim: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by hemolytic anemia, bone marrow failure and thrombosis, and is associated with high healthcare burden. We evaluated the cost–effectiveness of pegcetacoplan, a proximal complement-3 inhibitor (C3i), compared with the C5i, eculizumab and ravulizumab, in complement treatment-naive adults with PNH, from the US healthcare payer perspective. Materials & methods: A de novo cost–effectiveness model based on a Markov cohort structure evaluated lifetime (55-year) PNH costs and outcomes. The 6-month cycles of the model reflected the follow-up period of PRINCE (NCT04085601), an open-label trial of pegcetacoplan compared with eculizumab in C5i-naive patients. Data from PRINCE informed the clinical, safety and health-related quality of life outcomes in the model. Results: Pegcetacoplan was associated with lifetime cost savings of USD1,176,808 and USD213,062 relative to eculizumab and ravulizumab, respectively (largely attributed to reduced drug costs and blood transfusions), and additional quality-adjusted life years (QALYs) of 0.25 and 0.24. Conclusion: In patients with PNH who are treatment-naive, the base-case cost–effectiveness analysis, scenario analysis and sensitivity analysis showed both lifetime cost savings and increased QALYs associated with pegcetacoplan compared with eculizumab or ravulizumab in the USA.
Serologic Rebound after Stopping Azoles for Primary Pulmonary Coccidioidomycosis: A Case-Controlled Observational Study
Shah, P. , Ampel, Neil M. , Girardo, Marlene , Blair, Janis E. , Shah, Priyal J

Journal of Fungi | September 1, 2023 | Volume: 9 | Issue: 9 | Pages: 901

10.3390/jof9090901 | PMID 37755009 Get It

Background: We sought to characterize the outcomes of patients with primary pulmonary coccidioidomycosis whose post-treatment complement fixation (CF) titer increased by more than 2 dilutions (serologic rebound) after discontinuation of antifungal treatment. Methods. We conducted a retrospective chart review of patients with primary pulmonary coccidioidomycosis and identified immunocompetent, non-pregnant adults who received antifungal treatment and then experienced a serologic rebound after treatment discontinuation. We compared these to matched controls similarly treated who did not have serologic rebound. Results. Fifty-eight patients experienced serologic rebound. Thirty (52%) of these were associated with symptoms. Nine were associated with radiographic progression. The median time to serologic rebound was 3.5 months. Antifungal treatment was reinitiated in 37 (63.7%) patients. Four of the 58 (6.9%) with rebounded serology subsequently developed extra-thoracic dissemination. Compared with matched controls, patients with rebounded serology were more likely to have post-treatment symptoms, reinitiation of antifungal therapy, and a longer duration of clinical follow-up. However, they were not more likely to experience extra-thoracic dissemination. Conclusion: Serological rebound, manifested in at least 2-dilution rise of CF titer following antifungal treatment of primary pulmonary coccidioidomycosis, was uncommon, but resulted in longer clinical follow-up. Continued monitoring of such patients is important to identify the patients who develop subsequent symptoms, as well as extra-thoracic dissemination.
Long-Term Outcomes at Skeletal Maturity of Combined Pelvic and Femoral Osteotomy for the Treatment of Legg–Calve–Perthes Disease
Regan, Christina , Su, Alvin W.Y. , Stans, Anthony A. , Milbrandt, Todd A. , Shaughnessy, William J. , Grigoriou, Emmanouil , Regan, Christina M, Larson, A. Noelle

Journal of Clinical Medicine | September 1, 2023 | Volume: 12 | Issue: 17 | Pages: 5718

10.3390/jcm12175718 | PMID 37685785 Get It

Surgical treatment for Legg–Calve–Perthes disease (LCPD) is recommended for older children with moderate to severe disease. We sought to determine whether double osteotomies lead to improved radiologic outcomes compared to reported non-operative outcomes. Patients older than 6 years of age diagnosed with LCPD lateral pillar B or C who were treated with pelvic and femoral osteotomies were included. Radiologic outcomes and leg-length discrepancies were assessed using the Stulberg classification and were compared with the current literature. Fifteen hips in fourteen patients were treated with double osteotomy for LCPD, and seven had lateral pillar C disease (47%). The mean age at surgery was 8.6 years (range, 7.2–10.4) and the mean age at follow-up was 20.2 years (range, 14.2–35.6). At a mean 11.6-year follow-up (range: 6.3–25.2), double osteotomy resulted in 40% of patients having Stulberg I/II scores, 27% having Stulberg III scores, and 33% having Stulberg IV/V scores. The mean leg-length discrepancy was 1.4 cm in lateral pillar C patients compared to 0.8 cm in lateral pillar B patients. Four patients underwent additional surgeries, including two who required total hip arthroplasty. Double osteotomy as an alternative surgical procedure for the treatment of LCPD did not show improved outcomes when compared to historic non-operative cohorts.
Molecular analysis with pancreaseq® in evaluation and management of pancreatic cysts: A cohort of 28 patients
Ardor, Gokce Deniz , Hanna, Helena, Ozalp, Bora, Nassar, Aziza

Cytojournal | September 1, 2023 | Volume: 20 | Issue: No issue available | Pages: 23

10.25259/cytojournal_28_2023 | PMID 37681071 Get It

Objectives: Herein, we present the PancreaSeq® results of 28 patients and emphasize the usefulness of molecular testing in evaluation of pancreatic cysts. Material and Methods: A total of 10 (35.7%) non-diagnostic, 6 (21.4%) negative, 5 (17.8%) atypical, and 7 (25%) were positive for mucinous cystic neoplasm (MCN) pancreatic cyst aspirates were analyzed with PancreaSeq® at Mayo Clinic, Jacksonville between September 2021 and February 2023. Results: Three non-diagnostic, two negative, three atypical, and two positive for MCN cysts were positive for KRAS and GNAS mutations. They were interpreted as intraductal papillary mucinous neoplasm (IPMN) with low risk for progression to high-grade dysplasia/adenocarcinoma. One negative case was positive for KRAS and GNAS mutation and RNF43 copy number alteration. It was interpreted as IPMN with a low risk of progression. Two non-diagnostic, one negative, and two positive for MCN cysts were positive for KRAS mutation. All were interpreted as IPMN/MCNs with low risk of progression. One positive for MCN case was positive for GNAS mutation and ALK fusion and one positive for MCN case was positive for GNAS mutation, ALK fusion, and RNF43 copy number alteration. Both were interpreted as IPMN and their risk of progression was interpreted as not well understood. One atypical case was positive for KRAS and TP53 mutation and was interpreted as IPMN/ MCNs with a high risk of progression. VHL mutation was present in one non-diagnostic case. It was interpreted as serous cystadenoma and the risk for progression was low. Conclusion: Molecular analysis of pancreatic cysts with PancreaSeq® is useful in accurate diagnosis, especially when cytologic material is non-diagnostic and helps improve patient management.
A foundation to better care: Target product profile for haemophilia and Von Willebrand disease point‐of‐care diagnostics in low‐resource settings
Hagembe, Juliana , Toulon, Pierre , Haffar, Assad, Baumann, Alain, Bowyer, Annette , Montalvão, Silmara Aparecida de Lima , Brasi, Carlos Daniel De , Pierce, Glenn F. , de Lima Montalvão, Silmara , Pierce, Glenn F , Gouider, Emna , Chen, Dong

Haemophilia | September 1, 2023 | Volume: 29 | Issue: 5 | Pages: 1376-1381

10.1111/hae.14853 | PMID 37655507 Get It